#AS­CO24: Merus, tout­ing more Phase 2 da­ta, plots piv­otal head and neck can­cer tri­al in first-line set­ting

Last year
R&D

Cal­lid­i­tas’ rare dis­ease drug draws $1B+ buy­out of­fer from Japan­ese buy­er

Last year
Deals

BioN­Tech dou­bles down on ADC part­ner MediLink in new $1.8B biobucks pact

Last year
Startups
Deals

Af­ter 14 years call­ing part­ner­ing shots at Genen­tech/Roche, James Sabry is head­ed back in­to the biotech fray

Last year
People
Bioregnum

No­var­tis to seek ap­provals in two rare kid­ney dis­eases af­ter pos­i­tive Phase 3 tri­als

Last year
R&D

Pfiz­er's $1.5B cuts; Bio­gen's $1.15B buy­out; As­traZeneca's $80B am­bi­tion; RNA start­up merg­er; and more

Last year
Weekly

FDA ad­vi­so­ry com­mit­tee says risks of No­vo Nordisk’s once-week­ly in­sulin out­weigh ben­e­fits in type 1 di­a­betes ...

Last year
FDA+

Start­up Hims has long-term plans for cus­tom weight loss shots

Last year
Pharma
Health Tech

Pub­lic Cit­i­zen sues FDA over cit­i­zen pe­ti­tion on SS­RI sex­u­al side ef­fects la­bel­ing

Last year
FDA+
Law

FDA de­nies Ipsen's cit­i­zen pe­ti­tion for block­buster drug So­mat­u­line

Last year
Pharma
FDA+

Lil­ly bud­gets ad­di­tion­al $5.3B for tirzepatide API fac­to­ry in In­di­ana

Last year
Manufacturing

Ve­rastem's stock takes a hit af­ter shar­ing up­dat­ed fil­ing plans in ovar­i­an can­cer

Last year
R&D

#AS­CO24: A roundup of the lat­est da­ta from Merus, Mor­phoSys and oth­ers

Last year
R&D

HI-Bio out­lines da­ta that sparked $1.15B Bio­gen buy­out

Last year
R&D

No­vo re­ports 're­al­ly pow­er­ful' car­dio, death risk re­duc­tion for semaglu­tide in kid­ney dis­ease

Last year
R&D
Pharma

Zealand touts safe­ty of new ‘dou­ble-G’ drug de­spite mod­est weight loss in small tri­al

Last year
R&D

Idor­sia’s Jean-Paul Clozel re­tires as CEO, plots next steps; CRISPR Ther­a­peu­tics nabs CMO from Sanofi

Last year
People
Peer Review

J&J plans for capped, flex­i­ble dos­ing af­ter four pa­tient deaths in ear­ly study of ac­tini­um prostate can­cer drug

Last year
R&D

Mer­ck, Kelun trum­pet Phase 3 breast can­cer da­ta for an­ti-TROP2 ADC

Last year
R&D

Af­ter $4B Take­da deal, Nim­bus lays out ‘grand’ hopes for its next-gen im­munother­a­py drug

Last year
R&D

Pfiz­er shares the ADC da­ta that con­vinced it to start a Phase 3 lung can­cer tri­al

Last year
R&D
Pharma

Nu­va­tion Bio shares piv­otal Chi­na da­ta for can­cer drug from An­Heart buy­out

Last year
R&D
China

AS­CO ab­stracts are out, with da­ta for AD­Cs, Nim­bus' next-gen I/O drug and more

Last year
R&D
Pharma

Talc claimants file class ac­tion suit ac­cus­ing J&J of fraud over bank­rupt­cy moves

Last year
Pharma
Law
First page Previous page 152153154155156157158 Next page Last page
A service from the Financial Times